ropinirole tablets
ranbaxy pharmaceuticals canada inc. - ropinirole (ropinirole hydrochloride) - tablet - 0.25mg - ropinirole (ropinirole hydrochloride) 0.25mg - nonergot-derivative dopamine receptor agonists
ropinirole tablet
cobalt pharmaceuticals company - ropinirole (ropinirole hydrochloride) - tablet - 0.25mg - ropinirole (ropinirole hydrochloride) 0.25mg - nonergot-derivative dopamine receptor agonists
jamp-ropinirole tablet
jamp pharma corporation - ropinirole (ropinirole hydrochloride) - tablet - 0.25mg - ropinirole (ropinirole hydrochloride) 0.25mg - nonergot-derivative dopamine receptor agonists
ropinirole tablet
sanis health inc - ropinirole (ropinirole hydrochloride) - tablet - 0.25mg - ropinirole (ropinirole hydrochloride) 0.25mg - nonergot-derivative dopamine receptor agonists
mint-levocarb tablet
mint pharmaceuticals inc - levodopa; carbidopa - tablet - 250mg; 25mg - levodopa 250mg; carbidopa 25mg - dopamine precursors
parnate tranylcypromine 10mg film coated tablet
amdipharm mercury australia pty ltd - tranylcypromine sulfate, quantity: 13.68 mg (equivalent: tranylcypromine, qty 10 mg) - tablet, film coated - excipient ingredients: sucrose; erythrosine; magnesium stearate; gelatin; calcium sulfate dihydrate; maize starch; carnauba wax; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow; iron oxide red; iron oxide black; cochineal - indications as at 5 october 1998: treatment of major depression.
apo-levocarb tablets
apotex inc. - levodopa, carbidopa - tablets - 100mg+ 25mg
benztrop benztropine mesilate 2mg tablet bottle
phebra pty ltd - benzatropine mesilate, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - indicated for the treatment of all forms of parkinsonism. the treatment of extrapyramidal reactions (except tardive dyskinesia [see contraindications and precautions]) due to neuroleptic drugs.
eldepryl selegiline hydrochloride 5 mg tablet
orion pharma (aus) pty limited - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; maize starch; microcrystalline cellulose; mannitol - as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor) as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor)
sinemet 10/100 milligram tablets
imbat limited - carbidopa levodopa - tablets - 10/100 milligram